Background. The antiretroviral drug efavirenz is widely used during breastfeeding. Evaluating its safety requires an understanding of its breast milk pharmacokinetics, level of breastfed infants' exposure, and potential influence of polymorphisms in drug disposition genes.
Exclusive breastfeeding for the first 6 months of life, continued for up to 2 years with gradual introduction of safe and nutritionally adequate replacement feeding, is the recommended feeding option in the context of human immunodeficiency virus (HIV) infection in resource-limited settings [1] [2] [3] . The potential benefits of avoiding or early cessation of breastfeeding in this population are largely offset by increased infant morbidity/ mortality from causes other than HIV/AIDS, including malnutrition, diarrhea, and pneumonia [4] [5] [6] [7] . Motherto-child transmission (MTCT) during this period is prevented by maternal antiretroviral drugs (ARVs) started during pregnancy and continued until breastfeeding ends (Option B) or for life (Option B+) [8, 9] . The infant is given daily nevirapine post-exposure prophylaxis (PEP) from birth until 4-6 weeks old [8] , which reduces MTCT to <5% in these settings from the baseline 20%-45% without intervention [10] .
The current World Health Organization (WHO) guidelines recommend efavirenz (EFV) as the preferred non-nucleoside reverse transcriptase inhibitor component of first-line antiretroviral therapy (ART) for adults across different patient populations, including nursing mothers [11] . However, EFV is not licensed for use in children <3 months old or <3.5 kg because optimal dosing and safety have not been evaluated [12] . However, it is increasingly used by nursing mothers, and its presence in breast milk and breastfed infants' plasma has been reported [13, 14] but in limited numbers of mother-infant pairs and at single time points after maternal dose. Milk production, composition, and infant feeding patterns change during the dosing interval and may cause variations in the milk-to-plasma (M/P) concentration ratio, making single point estimates unreliable [15, 16] . In addition, the only study that reported EFV concentration in breast milk used skimmed milk [13] , which often yields lower drug concentrations than whole milk. A recently developed method for the quantification of EFV in dried breast milk spots [17] has now extended our ability to study the pharmacokinetics of EFV in whole milk during an entire dosing interval.
The influence of single-nucleotide polymorphisms (SNPs) in drug metabolizing enzymes, transporter and nuclear receptor genes on plasma EFV concentration is well established [18] . The interindividual variability observed in EFV plasma pharmacokinetics in different populations has been associated with such SNPs [19] . We previously hypothesized that SNPs may affect EFV excretion into breast milk and transfer to breastfed infants [20] . Understanding the pharmacokinetics of EFV in human breast milk during an entire dosing interval and potential differences introduced by genetic polymorphisms are crucial for an accurate estimation of infant exposure.
In the present study, associations between EFV concentrations in plasma and breast milk of nursing mother-infant pairs and SNPs in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2 genes were explored. We then investigated EFV plasma and breast milk pharmacokinetics and breastfed infants' exposure in genetically defined subgroups, stratified by the SNP with the highest predictive power.
METHODS

Patients
HIV-positive nursing mothers and their breastfed infants were recruited from 3 hospitals in Benue State, Nigeria: Bishop Murray Medical Centre, Makurdi; St Mary's Hospital, Okpoga; and St Monica's Hospital, Adikpo. Potentially eligible subjects were identified using the current prevention of MTCT (PMTCT) delivery register and invited to participate after an information session conducted in English and the local Tiv language. All participants gave prior written informed consent. Once subjects had signed a consent form, we ascertained eligibility by examining case notes and conducting a brief interview. The inclusion criteria included HIV positive and breastfeeding, enrolled in the PMTCT programme and started EFV-containing regimen during pregnancy. Exclusion criteria (assessed at enrolment) included exclusive formula feeding, mixed feeding in infants less than 6 months old, opportunistic infections (eg, tuberculosis, pneumonia), severe maternal or infant illness, and maternal or infant treatment with drugs or herbal medication with known or uncertain interaction with EFV. The protocol and the materials transfer agreement were approved by the National Health Research Ethics Committee (NHREC), Abuja, Nigeria and Ethics and Research Committee, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria. Clinicaltrials.gov ID: NCT02269462.
Study Design
This was an observational study conducted in 2 phases. In the preliminary phase, we explored associations between 12 SNPs in drug disposition genes and mid-dose efavirenz concentrations in plasma and breast milk in an unselected cohort of HIV-positive nursing mothers and their breastfed infants. In the intensive pharmacokinetic phase, the SNP independently associated with the highest predictive power was used to stratify mother-infant pairs into 3 groups: noncarriers, heterozygotes, and homozygotes. Randomly selected mother-infant pairs from each group were re-recruited and invited for the intensive pharmacokinetic phase.
Samples Collection
In the preliminary phase, paired dried blood spots (DBS) and dried breast milk spots samples were collected from mothers and infants at a single, recorded time point post-dose. In the intensive pharmacokinetic phase, maternal DBS and dried breast milk spots were collected at 0.5, 1, 2, 4, 8, 12, and 24 hours after an observed evening dose of 600 mg EFV and stored as previously described [17] . DBS samples were collected from infants at 2 hours and 8 hours after maternal EFV dose in the intensive pharmacokinetic phase. To reflect real-life situations, infant feeding times were not controlled; all infants were breastfed on demand. In addition, mothers took standard local meals about 30 minutes before drug administration. Samples were shipped at ambient temperature to the University of Liverpool, United Kingdom, for analysis.
DNA Extraction and SNP Genotyping
Genomic DNA was extracted using E.Z.N.A. Blood DNA Mini Kit (Omega Bio-Tek, Inc., Norcross, Georgia) in accordance with the manufacturer's protocol. DNA was quantified spectrophotometrically using NanoDrop (Thermo Fisher Scientific Inc., Wilmington, Delaware) before storage at −20°C. Genotyping was performed by real-time polymerase chain reaction (PCR) on a DNA Engine Chromo4 system (Bio-Rad Laboratories, Inc., Hercules, California). The Supplementary Material contains further details about TaqMan SNP Genotyping assays.
EFV Quantification and Pharmacokinetic Analysis
EFV in DBS and dried breast milk spots was quantified using previously described LC-MS/MS methods [17, 21] . Plasma concentrations were determined using [DBS [EFV] /(1-HCT)]*0.995, where DBS [EFV] is EFV concentration in DBS, HCT is the patient-specific hematocrit, and 0.995 is the fraction of EFV bound to plasma protein [22] . Minimum (C min ) and maximum (C max ) plasma concentrations were determined by direct inspection. The area under the concentration-time curve during the dosing interval (AUC 0-24 ) was calculated using the trapezoidal rule, and the apparent clearance (Cl/F) was calculated by dividing dose by AUC 0-24 . Maximum (InfantDose max ) and average (InfantDose avg ) infant EFV doses from breast milk were calculated using equations (1) and (2), respectively. Pediatric dose (for children aged ≥3 months and weighing ≥3.5 kg [12] ) weight-adjusted exposure index (EI paediatric ) and maternal dose weight-adjusted exposure index (EI maternal ) were calculated using equations (3) and (4) where 150 is the average volume of infant daily milk intake in mL/kg/day; MilkC max is the maximum EFV concentration in breast milk (µg/mL); MilkAUC 0-24 is EFV breast milk AUC 0-24 (µg.h/mL); 24 is the dosing interval in h; Dose paediatric is the weight-adjusted licensed pediatric dose of EFV (µg/kg/day); Dose maternal is the weight-adjusted licensed adult dose of EFV (µg/kg/day).
Statistical Analysis
Compliance with Hardy-Weinberg Equilibrium was tested as previously described [23] . Data were subjected to KolmogorovSmirnov normality test prior to statistical analysis. Relationships between continuous variables were tested by Pearson or Spearman correlation. Univariate linear regression analysis was conducted to identify variables associated with EFV concentrations in maternal plasma, infant plasma, and breast milk. Bonferroni correction was used to adjust for multiple testing. Independent variables with Bonferroni P value ≤.1 in the univariate analysis were included in a multivariate stepwise linear regression analysis. Differences in EFV concentrations and pharmacokinetic parameters between patient groups were investigated using 1-way analysis of variance (ANOVA) and Kruskal-Wallis or Mann-Whitney U test. Trend across groups was investigated using Cuzick test on StatDirect (StatsDirect Ltd, Altrincham, Cheshire, UK). Post hoc analysis of statistical power achieved was conducted using G*Power version 3.9.1.2 (Heinrich-Heine-University, Düsseldorf, Germany). All other analyses were conducted using IBM SPSS Statistics version 20.0 (IBM, Armonk, New York) and GraphPad Prism (GraphPad Software, Inc., La Jolla, California). 
RESULTS
Patients' Characteristics
Between December 2012 and October 2013, 134 eligible HIVpositive nursing mothers and their breastfed infants were recruited. Maternal and infant characteristics are summarized in Table 1 . The mean (SD) duration on current ARV regimen was 17.6 (14.1) months, starting with baseline CD4 count of 380 (217) c/mm 3 . Most patients were taking EFV, emtricitabine and tenofovir (65%; 87/134) or EFV, lamivudine and zidovudine (32%; 43/134). Infants <6 weeks of age (22%; 29/ 134) were taking nevirapine PEP. Genotype frequencies are summarized in Table 1 . All 12 SNPs were in Hardy-Weinberg equilibrium.
Factors Associated With Plasma and Breast Milk EFV Concentrations
In the preliminary phase, samples were collected at 14.00 hours (0.50-21.5) after maternal EFV dose, and median (range) maternal plasma, breast milk, and infant plasma EFV concentrations were 2310 ng/mL (632-8880), 2280 ng/mL (475-10 800) and 173 ng/mL (46.0-4630), respectively ( Table 2 ). There were significant correlations in EFV concentrations between maternal plasma and breast milk, P < .0001, Pearson r = 0.73 (0.62, 0.81); maternal plasma and infant plasma, P < .0001; Pearson r = 0.58 (0.45, 0.69); and breast milk and infant plasma, P < .0001; Pearson r = 0.46 (0.28, 0.61) (Figure 1 ). Of the 12 SNPs, only maternal CYP2B6 516G>T (rs3745274) was independently associated with EFV concentrations in maternal plasma, breast milk, and infant plasma. In addition, infant age and time after maternal EFV dose were independently associated with infant plasma EFV concentration. The regression coefficients (β), which represents incremental change in log 10 EFV concentration per unit change in patient characteristics, are presented in Table 3 . In a separate analysis, both infant CYP2B6 516G>T (P = .019) and composite infant/maternal CYP2B6 516G>T genotypes (P = .006) were independently associated with infant log 10 EFV concentration after adjusting for breast milk concentration and infant age with β values of 0.105 (0.018, 0.193) and 0.033 (0.010, 0.057), respectively. More than 99% statistical power was achieved in the multiple linear regressions for plasma (maternal and infant) and breast milk concentrations. Significant differences were observed in maternal plasma EFV concentrations based on CYP2B6 516G>T genotypes (P < .0001): GG (n = 42), 1660 ng/mL (632-3610); GT (n = 52), 2390 ng/mL (951-8880); and TT (n = 23), 5400 ng/mL (1920-8110). Breast milk concentrations also varied based on CYP2B6 516G>T genotypes (P = .0002): GG, 1610 ng/mL (475-5580); GT, 2370 ng/mL (713-10 300); and TT, 4070 ng/mL (995-10 800). A similar trend was observed for infant plasma concentrations based on both maternal and infant CYP2B6 516G>T genotypes (Table 2 and Figure 2 ). After excluding infants <10 days old with residual intrauterine exposure, plasma EFV concentrations in infants based on maternal CYP2B6 516G>T genotypes were: GG: 120 ng/mL (46.0-429); GT: 157 ng/mL (48.5-590); and TT: 329 ng/mL (75.5-705). There was a significant trend toward higher infant plasma EFV concentration from GG/GG to TT/TT composite maternal/ infant CYP2B6 516G>T genotype, Cuzick's test for trend P value <.0001 ( Figure 3) .
Only maternal CYP2B6 516G>T (rs3745274) was used to stratify mother-infant pairs, and a total of 29 (GG, 10; GT, 11; TT, 8) were invited for the intensive pharmacokinetic phase.
Full Pharmacokinetic Profiles of EFV in Plasma and Breast Milk
EFV concentration-time profiles in maternal plasma and breast milk in the entire population and in CYP2B6 516GG, CYP2B6 516GT, and CYP2B6 516TT groups are presented in Figure 4 . The corresponding pharmacokinetic parameters are presented in Table 2 . In pooled analysis, median (range) pharmacokinetic parameters in maternal plasma vs breast milk were: AUC 0-24 , 60 700 ng.h/mL (26 800-177 000) vs 68 500 ng.h/mL (26 300-257 000); C max , 4630 ng/mL (2050-9760) vs 5390 ng/mL (1430-18 400); and C min , 2030ng/mL (755-6740) vs 1680 ng/mL (316-9570). Wide intra-and inter-individual variability in the M/P ratio during the dosing interval was observed. The time averaged M/P concentration ratio was 1.10 (0.57-1.71) and M/P AUC 0-24 ratio was 1.13 (0.50-1.93) ( Table 2 and Figure 4 ). EFV pharmacokinetic parameters in plasma and breast milk differed significantly between patients stratified by CYP2B6 516G>T genotypes (P < .05). As with plasma, EFV breast milk AUC 0-24 , C max and C min were significantly lower in nursing mothers with CYP2B6 516GG compared with CYP2B6 516GT or CYP2B6 516TT genotypes (Table 2 and Figure 4 ). The study was sufficiently powered to detect differences between GG vs TT (100% power) and GT vs TT (99.9% power) but not between GG vs GT groups (26% power).
Breastfed Infants' Exposure to EFV From Breast Milk
The average infant EFV dose from breast milk, calculated using AUC 0-24 -derived average milk concentration during the dosing interval and 150 mL/kg/day as average milk intake, was 428 µg/kg/day (164-1610). Using EFV C max in breast milk as the maximum breast milk concentration, the maximum EFV dose from breast milk was 809 µg/kg/day (215-2760). In pooled analysis, pediatric dose (for children aged ≥3 months and weighing ≥3.5 kg [12] ) weight-adjusted exposure index was 4.05% (1.08-13.8) and maternal dose weight-adjusted exposure index was 7.69% (2.04-26.2). When stratified by maternal CYP2B6 516G>T, paediatric and maternal dose weight-adjusted exposure indices were highest in CYP2B6 516TT group with values of 6.70 (4.36-13.8) and 12.7 (8.28-26.2), respectively. Infant plasma concentrations did not change significantly during the dosing interval, with no significant differences (P > .05) between concentrations at 2 hours and 8 hours after maternal EFV dose, with an average of 157 ng/mL (28.6-1360), highest in infants of CYP2B6 516TT mothers with a value of 315 ng/mL (108-1360) ( Table 2 and Figure 5 ). Infant EFV concentration decreased from 1590 ng/mL (190-4631) in 2-8 days old infants, to 194 ng/mL (51.9-705) in 9 days-3 months old, 149 ng/mL (51.8-325) in >3-6 months old, and 102 ng/mL (40.8-590) in >6 months old. All infants in this cohort achieved EFV concentrations above the IC 50 of 0.51 ng/mL for wild-type HIV-1 in protein-free medium, and more than 75% achieved greater than 100 × IC 50 [24] .About 96% (129/134) achieved the protein binding-corrected IC 50 of 36 ng/mL reported by Acosta et al [25] , but only 57% (76/ 134) achieved the corresponding IC 95 of 126 ng/mL.
DISCUSSION
To our knowledge, this is the first study describing EFV pharmacokinetics in human breast milk during the entire dosing The boldface highlights associations that were statistically significant.
Abbreviations: CI, confidence interval; EFV, efivarenz. a β is regression coefficient, which represents incremental change in log 10 EFV concentration per unit change in a patient characteristic.
interval in genetically defined subgroups of nursing mothers. This approach highlights possible worst case scenarios of infant exposure to drugs from breast milk in terms of maternal drug metabolism capacity and infant feeding time. It is also the largest study of EFV excretion into human breast milk and transfer to breastfed infants. Findings indicated that maternal CYP2B6 516G>T was associated with EFV concentrations in maternal plasma, breast milk and infant plasma. With a pediatric dose weight-adjusted exposure index of 4.05% (1.08-13.8), the overall infant exposure to maternal EFV from breast milk was relatively low, highest in infants of mothers with the CYP2B6 516TT genotype at 6.70% (4.36-13.8). The infant plasma EFV concentrations also varied depending on maternal and infant CYP2B6 516G>T genotypes, suggesting a role for CYP2B6 SNPs in EFV disposition in neonates and supporting a recent Food and Drug Administration (FDA) recommendation for CYP2B6 516G>T-guided dosing of EFV in children between 3 months and 3 years old [12] . CYP2B6 is known to be expressed in infants and to contribute to EFV pharmacokinetic variability in children [26, 27] . The relatively high infant plasma EFV concentrations in the early neonatal period which rapidly declined after day 8 is consistent with observations of in utero exposure to EFV and persistence in plasma up to day 7 after delivery [28, 29] . Significant increases in the expression of CYP2B6 after the neonatal period may also play a role [26] . The EFV dose below which there is no clinically significant effect in infants is unknown. An exposure index of no more than 10% weight-adjusted therapeutic pediatric dose has been proposed as a safety threshold for infant exposure to maternal drugs from breast milk [16] . There was no report of drug-related adverse events in any infants in the present study, suggesting EFV ingestion through breast milk is unlikely to result in toxicity. However, exposure to subtherapeutic EFV concentrations through breast milk raises concerns about potential development of resistance in the rare event of PMTCT failure as reported for other drugs [30, 31] . About 96% and 57% of infants achieved plasma EFV concentrations above the published protein binding-corrected IC 50 and IC 95 , respectively, for wild-type human immunodeficiency virus type 1 (HIV-1) [25] .
Studies in chronically infected patients have demonstrated limited compartmentalization and clonal amplification of functional HIV-1 in human breast milk, suggesting ongoing blood-to-breast milk seeding of virus, followed by transient local replication in breast milk [32, 33] . Therefore, therapeutic concentrations of EFV in breast milk may play an important role in preventing ongoing replication of HIV in mammary glands and development of resistance [34] , which may otherwise be passed to infants if PMTCT fails [35, 36] . These findings support recent updates in treatment guidelines recommending the use of EFV-based Table 2 . Abbreviation: IQR, interquartile range. ART started during pregnancy and continued until breastfeeding ends (Option B) or for life (Option B+) for PMTCT [11] .
These findings should be interpreted in the context of certain limitations. The study was not adequately powered to detect differences in pharmacokinetic parameters between the GG (n = 10) vs GT (n = 11) groups; only 26% statistical power was achieved. Although we observed higher EFV concentrations in 22% of the infants receiving nevirapine prophylaxis (data not shown), we are unable to make firm conclusions about the interaction because the prophylaxis is given to younger infants who also have residual EFV from intrauterine exposure. As a result of practical challenges associated with plasma collection in resource-limited settings, samples were collected as DBS. However, the negative bias associated with EFV quantification in DBS was adequately compensated using a validated method correcting for patient hematocrit and protein binding [37] . Dried breast milk spot allowed for EFV quantification in whole milk [17] , a major difficulty associated with liquid milk [38] .
In conclusion, most breastfed infants are exposed to <10% of weight-adjusted licensed paediatric dose of EFV through breast milk. Further studies to monitor the long-term safety, including possible emergence of resistance in infants who may become infected if PMTCT fails, are now warranted.
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